Copyright Reports & Markets. All rights reserved.

Global and China Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Growth Rate by Type: 2020 VS 2026
    • 1.2.2 ACH-4471
    • 1.2.3 ALN-CC5
    • 1.2.4 ALXN-1210
    • 1.2.5 AMY-101
    • 1.2.6 APL-2
    • 1.2.7 Others
  • 1.3 Market by Application
    • 1.3.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Application: 2020 VS 2026
    • 1.3.2 Hospital
    • 1.3.3 Clinic
    • 1.3.4 Others
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Perspective (2015-2026)
  • 2.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Growth Trends by Regions
    • 2.2.1 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Paroxysmal Nocturnal Hemoglobinuria Treatment Historic Market Share by Regions (2015-2020)
    • 2.2.3 Paroxysmal Nocturnal Hemoglobinuria Treatment Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Paroxysmal Nocturnal Hemoglobinuria Treatment Players by Market Size
    • 3.1.1 Global Top Paroxysmal Nocturnal Hemoglobinuria Treatment Players by Revenue (2015-2020)
    • 3.1.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Market Share by Players (2015-2020)
  • 3.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue
  • 3.4 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Concentration Ratio
    • 3.4.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue in 2019
  • 3.5 Key Players Paroxysmal Nocturnal Hemoglobinuria Treatment Area Served
  • 3.6 Key Players Paroxysmal Nocturnal Hemoglobinuria Treatment Product Solution and Service
  • 3.7 Date of Enter into Paroxysmal Nocturnal Hemoglobinuria Treatment Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Paroxysmal Nocturnal Hemoglobinuria Treatment Breakdown Data by Type (2015-2026)

  • 4.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Historic Market Size by Type (2015-2020)
  • 4.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Forecasted Market Size by Type (2021-2026)

5 Paroxysmal Nocturnal Hemoglobinuria Treatment Breakdown Data by Application (2015-2026)

  • 5.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Historic Market Size by Application (2015-2020)
  • 5.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (2015-2026)
  • 6.2 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2015-2020)
  • 6.3 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2015-2020)
  • 6.4 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2015-2020)
    • 6.4.1 United States
    • 6.4.2 Canada

7 Europe

  • 7.1 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (2015-2026)
  • 7.2 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2015-2020)
  • 7.3 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2015-2020)
  • 7.4 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2015-2020)
    • 7.4.1 Germany
    • 7.4.2 France
    • 7.4.3 U.K.
    • 7.4.4 Italy
    • 7.4.5 Russia
    • 7.4.6 Nordic
    • 7.4.7 Rest of Europe

8 China

  • 8.1 China Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (2015-2026)
  • 8.2 China Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2015-2020)
  • 8.3 China Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2015-2020)
  • 8.4 China Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Region (2015-2020)
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 South Korea
    • 8.4.4 Southeast Asia
    • 8.4.5 India
    • 8.4.6 Australia
    • 8.4.7 Rest of Asia-Pacific

9 Japan

  • 9.1 Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (2015-2026)
  • 9.2 Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2015-2020)
  • 9.3 Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2015-2020)
  • 9.4 Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2015-2020)
    • 9.4.1 Mexico
    • 9.4.2 Brazil

10 Southeast Asia

  • 10.1 Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (2015-2026)
  • 10.2 Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2015-2020)
  • 10.3 Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2015-2020)
  • 10.4 Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2015-2020)
    • 10.4.1 Turkey
    • 10.4.2 Saudi Arabia
    • 10.4.3 UAE
    • 10.4.4 Rest of Middle East & Africa

11 Key Players Profiles

  • 11.1 Achillion Pharmaceuticals Inc
    • 11.1.1 Achillion Pharmaceuticals Inc Company Details
    • 11.1.2 Achillion Pharmaceuticals Inc Business Overview
    • 11.1.3 Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
    • 11.1.4 Achillion Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020))
    • 11.1.5 Achillion Pharmaceuticals Inc Recent Development
  • 11.2 Akari Therapeutics Plc
    • 11.2.1 Akari Therapeutics Plc Company Details
    • 11.2.2 Akari Therapeutics Plc Business Overview
    • 11.2.3 Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
    • 11.2.4 Akari Therapeutics Plc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
    • 11.2.5 Akari Therapeutics Plc Recent Development
  • 11.3 Alexion Pharmaceuticals Inc
    • 11.3.1 Alexion Pharmaceuticals Inc Company Details
    • 11.3.2 Alexion Pharmaceuticals Inc Business Overview
    • 11.3.3 Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
    • 11.3.4 Alexion Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
    • 11.3.5 Alexion Pharmaceuticals Inc Recent Development
  • 11.4 Alnylam Pharmaceuticals Inc
    • 11.4.1 Alnylam Pharmaceuticals Inc Company Details
    • 11.4.2 Alnylam Pharmaceuticals Inc Business Overview
    • 11.4.3 Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
    • 11.4.4 Alnylam Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
    • 11.4.5 Alnylam Pharmaceuticals Inc Recent Development
  • 11.5 Amgen Inc
    • 11.5.1 Amgen Inc Company Details
    • 11.5.2 Amgen Inc Business Overview
    • 11.5.3 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
    • 11.5.4 Amgen Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
    • 11.5.5 Amgen Inc Recent Development
  • 11.6 Apellis Pharmaceuticals Inc
    • 11.6.1 Apellis Pharmaceuticals Inc Company Details
    • 11.6.2 Apellis Pharmaceuticals Inc Business Overview
    • 11.6.3 Apellis Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
    • 11.6.4 Apellis Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
    • 11.6.5 Apellis Pharmaceuticals Inc Recent Development
  • 11.7 F. Hoffmann-La Roche Ltd
    • 11.7.1 F. Hoffmann-La Roche Ltd Company Details
    • 11.7.2 F. Hoffmann-La Roche Ltd Business Overview
    • 11.7.3 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
    • 11.7.4 F. Hoffmann-La Roche Ltd Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
    • 11.7.5 F. Hoffmann-La Roche Ltd Recent Development
  • 11.8 ISU ABXIS Co Ltd
    • 11.8.1 ISU ABXIS Co Ltd Company Details
    • 11.8.2 ISU ABXIS Co Ltd Business Overview
    • 11.8.3 ISU ABXIS Co Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
    • 11.8.4 ISU ABXIS Co Ltd Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
    • 11.8.5 ISU ABXIS Co Ltd Recent Development
  • 11.9 Novartis AG
    • 11.9.1 Novartis AG Company Details
    • 11.9.2 Novartis AG Business Overview
    • 11.9.3 Novartis AG Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
    • 11.9.4 Novartis AG Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
    • 11.9.5 Novartis AG Recent Development
  • 11.10 NovelMed Therapeutics Inc
    • 11.10.1 NovelMed Therapeutics Inc Company Details
    • 11.10.2 NovelMed Therapeutics Inc Business Overview
    • 11.10.3 NovelMed Therapeutics Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
    • 11.10.4 NovelMed Therapeutics Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
    • 11.10.5 NovelMed Therapeutics Inc Recent Development
  • 11.11 Omeros Corp
    • 10.11.1 Omeros Corp Company Details
    • 10.11.2 Omeros Corp Business Overview
    • 10.11.3 Omeros Corp Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
    • 10.11.4 Omeros Corp Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
    • 10.11.5 Omeros Corp Recent Development
  • 11.12 Ra Pharmaceuticals Inc
    • 10.12.1 Ra Pharmaceuticals Inc Company Details
    • 10.12.2 Ra Pharmaceuticals Inc Business Overview
    • 10.12.3 Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
    • 10.12.4 Ra Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
    • 10.12.5 Ra Pharmaceuticals Inc Recent Development
  • 11.13 Regeneron Pharmaceuticals Inc
    • 10.13.1 Regeneron Pharmaceuticals Inc Company Details
    • 10.13.2 Regeneron Pharmaceuticals Inc Business Overview
    • 10.13.3 Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
    • 10.13.4 Regeneron Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
    • 10.13.5 Regeneron Pharmaceuticals Inc Recent Development
  • 11.14 Regenesance BV
    • 10.14.1 Regenesance BV Company Details
    • 10.14.2 Regenesance BV Business Overview
    • 10.14.3 Regenesance BV Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
    • 10.14.4 Regenesance BV Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
    • 10.14.5 Regenesance BV Recent Development

12 Analyst's Viewpoints/Conclusions

    13 Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Global Paroxysmal Nocturnal Hemoglobinuria Treatment Scope and Market Size
    Paroxysmal Nocturnal Hemoglobinuria Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Paroxysmal Nocturnal Hemoglobinuria Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    Market segment by Type, the product can be split into
    ACH-4471
    ALN-CC5
    ALXN-1210
    AMY-101
    APL-2
    Others

    Market segment by Application, split into
    Hospital
    Clinic
    Others

    Based on regional and country-level analysis, the Paroxysmal Nocturnal Hemoglobinuria Treatment market has been segmented as follows:
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Rest of Europe
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Rest of Asia-Pacific
    Latin America
    Mexico
    Brazil
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE
    Rest of Middle East & Africa

    In the competitive analysis section of the report, leading as well as prominent players of the global Paroxysmal Nocturnal Hemoglobinuria Treatment market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
    The key players covered in this study
    Achillion Pharmaceuticals Inc
    Akari Therapeutics Plc
    Alexion Pharmaceuticals Inc
    Alnylam Pharmaceuticals Inc
    Amgen Inc
    Apellis Pharmaceuticals Inc
    F. Hoffmann-La Roche Ltd
    ISU ABXIS Co Ltd
    Novartis AG
    NovelMed Therapeutics Inc
    Omeros Corp
    Ra Pharmaceuticals Inc
    Regeneron Pharmaceuticals Inc
    Regenesance BV

    Buy now